Venturi Wealth Management LLC Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Venturi Wealth Management LLC bought a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,000 shares of the biopharmaceutical company’s stock, valued at approximately $33,000.

A number of other institutional investors have also recently bought and sold shares of AGIO. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 363 shares during the period. KBC Group NV lifted its position in Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 611 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Agios Pharmaceuticals by 6.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company’s stock valued at $539,000 after buying an additional 688 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Agios Pharmaceuticals by 10.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,092 shares of the biopharmaceutical company’s stock valued at $397,000 after buying an additional 1,150 shares in the last quarter. Finally, Quest Partners LLC increased its holdings in Agios Pharmaceuticals by 139.6% in the 3rd quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 1,283 shares in the last quarter.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now directly owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. This represents a 12.92 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.93% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. HC Wainwright began coverage on shares of Agios Pharmaceuticals in a research report on Monday. They set a “buy” rating and a $58.00 price target for the company. Scotiabank upped their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Finally, Royal Bank of Canada increased their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $56.57.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO opened at $35.19 on Wednesday. The business’s fifty day moving average price is $34.01 and its two-hundred day moving average price is $42.92. The firm has a market capitalization of $2.02 billion, a PE ratio of 3.10 and a beta of 0.88. Agios Pharmaceuticals, Inc. has a 1-year low of $27.14 and a 1-year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Equities research analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.